TCRT · Alaunos Therapeutics, Inc.
$1.93
-0.06 (-3.02%)
At close · Aug 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements which raises substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$4.90M
Shares
2.54M
Registered funds — mutual funds, ETFs and closed-end funds — whose latest Form N-PORT portfolio report holds this stock, matched by the stock's CUSIP. Each row is one fund position with its size, value and weight in that fund.
Funds holding TCRT
9 fund positions| Fund | Ticker | Balance | Value | % of Fund | Side | Reported | Open |
|---|---|---|---|---|---|---|---|
| Invesco DWA NASDAQ Momentum ETF | CVY | 59,208 | $233,280 | 0.46% | Long | 2020-01-31 | |
| Goldman Sachs Human Evolution ETF | GBIL | 49,825 | $140,008 | 0.29% | Long | 2020-08-31 | |
| Fidelity Extended Market Index Fund | — | 15,224 | $44,454 | 0.00% | Long | 2026-05-31 | |
| VANGUARD EXTENDED MARKET INDEX FUND | — | 14,063 | $40,220 | 0.00% | Long | 2026-03-31 | |
| Defiance Nasdaq Junior Biotechnology ETF | ABUF | 4,935 | $8,982 | 0.12% | Long | 2021-09-30 | |
| Fidelity Total Market Index Fund | — | 2,376 | $6,938 | 0.00% | Long | 2026-05-31 | |
| Fidelity Series Total Market Index Fund | — | 2,317 | $6,766 | 0.00% | Long | 2026-05-31 | |
| iShares Evolved U.S. Innovative Healthcare ETF | AGRH | 3,344 | $3,912 | 0.01% | Long | 2022-07-31 | |
| Fidelity Nasdaq Composite Index Fund | — | 1,117 | $3,262 | 0.00% | Long | 2026-05-31 |
Showing 1–9 of 9 positions
Key facts
CIK
1107421
CUSIP
98973P309
13F (30d)
30 filings
30 filers
Visit website
Investor relations